An update on medical management of Graves' ophthalmopathy

Journal of Endocrinological Investigation

Volumn 28, Issue 7, 2005, Pages 469-478

  Bartalena, L ^a   Marcocci, C ^b   Tanda, M L ^a   Piantanida, E ^a   Lai, A ^a   Marino M ^b   Pinchera, A ^b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Antioxidants; Glucocorticoids; Graves' ophthalmopathy; Orbital radiotherapy; Somatostatin analogs; Thyroid eye disease; Thyroid associated orbitopathy

Indexed keywords

ALLOPURINOL; ANTIOXIDANT; ETANERCEPT; GLUCOCORTICOID; METHYLPREDNISOLONE; NICOTINAMIDE; PENTOXIFYLLINE; PIOGLITAZONE; PLACEBO; PREDNISONE; SOMATOSTATIN DERIVATIVE; TRIAMCINOLONE ACETATE; DRUG DERIVATIVE; SOMATOSTATIN;

CLINICAL TRIAL; CUSHINGOID SYNDROME; DECOMPRESSION SURGERY; DEPRESSION; DISEASE COURSE; ENDOCRINE OPHTHALMOPATHY; EYE SURGERY; GASTRITIS; GLUCOSE INTOLERANCE; HEPATITIS; HUMAN; HYPERTENSION; LIVER INJURY; LIVER TOXICITY; REVIEW; RISK ASSESSMENT; RISK FACTOR; CONTROLLED CLINICAL TRIAL; GRAVES DISEASE; HOSPITALIZATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ANTIOXIDANTS; DISEASE PROGRESSION; GLUCOCORTICOIDS; GRAVES DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SOMATOSTATIN;

EID: 26944433118     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03347230     Document Type: Review

References (62)

1. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000, 21: 168-99.
2. Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 2004, 27: 259-64.
3. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003, 24: 802-35.
4. Bartalena L. Graves' ophthalmopathy: Search for thyroid autoantigen(s) continues. J Endocrinol Invest 2005, 28: 396-7.
5. Marcocci C, Marinò M, Rocchi R, Menconi F, Morabito E, Pinchera A. Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 272-80.
6. Bartalena L, Tanda ML, Piantanida E, Lai A, Pinchera A. Relationship between management of hyperthyroidism and course of the ophthalmopathy. J Endocrinol Invest 2004, 27: 288-94.
7. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001, 144: 311-8.
8. Bartalena L, Marcocci C, Tanda ML, Pinchera A. Management of thyroid eye disease. Eur J Nucl Med 2002, 29 (Suppl 2): S458-65.
9. Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004, 88: 1380-6.
10. Goldberg RA. Orbital steroid injections. Br J Ophthalmol 2004, 88: 1359-60.
11. Kendall-Taylor P, Crombie AL, Stephenson AM, Hardwick M, Hall R. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988, 297: 1574-8.
12. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001, 86: 3562-7.
13. Kauppinen-Makelin R, Karma A, Leinonen E, et al. High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalmol Scand 2002, 80: 316-21.
14. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004, 14: 403-6.
15. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 2000, 10: 521.
16. Salvi M, Vannucchi G, Sbrozzi F, et al. Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associated ophthalmopathy in a patient with Hashimoto's thyroiditis: case report. Thyroid 2004, 14: 631-4.
17. Dourakis SP, Sevastianos VA, Kalipi P. Acute severe steato-hepatitis related to prednisolone therapy. Am J Gastroenterol 2002, 97: 1074-5.
18. Bartalena L, Marcocci C, Tanda ML, et al. Orbital radiotherapy for Graves' ophthalmopathy. Thyroid 2002, 12: 245-50.
19. Kahaly GJ, Rosler H-P, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000, 85: 102-8.
20. Bartalena L, Marcocci C, Pinchera A. Orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2004, 89: 13-4.
21. Bartley GB, Gorman CA. The Mayo Orbital Radiotherapy for Graves' Ophthalmopathy (ORGO) study: lessons learned. Ophthalmic Plast Reconstr Surg 2002, 18: 170-2.
22. Kazim M. Radiotherapy for Graves orbitopathy: the Columbia University experience. Ophthalmic Plast Reconstr Surg 2002, 18: 173-4.
23. Wiersinga WM. Retrobulbar irradiation in Graves orbitopathy: the Dutch experience. Ophthalmic Plast Reconstr Surg 2002, 18: 175-6.
24. Cockerham KP, Kennerdell JS. Does radiotherapy have a role in the management of thyroid orbitopathy? View 1. Br J Ophthalmol 2002, 86: 102-4.
25. Mourits MP. Does radiotherapy have a role in the management of thyroid orbitopathy? View 2. Br J Ophthalmol 2002, 86: 104-6.
26. Bartalena L, Marcocci C, Gorman CA, Wiersinga WM, Pinchera A. Orbital radiotherapy for Graves' ophthalmopathy: useful or useless? Safe or dangerous? J Endocrinol Invest 2003, 26: 5-16.
27. Mourits MP, van Kempen-Harteveld ML, Garcia Garcia MB, Koppeschaar HPF, Tick L, Terwee CB. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000, 355: 1505-9.
28. Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004, 89: 15-20.
29. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomised, double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993, 342: 949-54.
30. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001, 108: 1523-34.
31. Schaefer U, Hesselmann S, Micke O, et al. A long-term follow-up study after retro-orbital irradiation for Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys 2002, 52: 192-7.
32. Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003, 88: 3561-6.
33. Wakelkamp IMMJ, Tan H, Saeed P, et al. Orbital irradiation for Graves' ophthalmopathy. Is it safe? A long-term follow-up study. Ophthalmology 2004, 111: 1557-62.
34. Robertson DM, Buettner H, Gorman CA, et al. Retinal microvascular abnormalities in patients treated with external radiation for Graves ophthalmopathy. Arch Ophthalmol 2003, 121: 652-7.
35. Pasquali D, Vassallo P, Esposito D, Bonavolontà G, Bellastella A, Sinisi AA. Somatostatin gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000, 25: 63-71.
36. Pasquali D, Notaro A, Bonavolontà G, Vassallo P, Bellastella A, Sinisi AA. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissue in Graves' disease. J Clin Endocrinol Metab 2002, 87: 5125-9.
37. Kahaly GJ. Recent developments in Graves' ophthalmopathy imaging. J Endocrinol Invest 2004, 27: 254-8.
38. Bartalena L, Tanda ML, Piantanida E, Lai A. The role of somatostatin analogs in the management of Graves' ophthalmopathy. J Endocrinol Invest 2003, 26 (Suppl 8): 109-13.
39. Krassas GE. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 281-7.
40. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004, 89: 5910-5.
41. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with Graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005, 90: 841-8.
42. Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves' ophthalmopathy: do they bounce off like a rubber bullet? J Clin Endocrinol Metab 2004, 89: 5908-9.
43. Saveanu A, Gunz G, Dufour H, Enjalbert A, Culler MD, Jaquet P. Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J Endocrinol Invest 2003, 26 (Suppl to no. 8): 4-7.
44. Boerlin V, van der Hoek J, Beglinger Ch, et al. New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003, 26 (Suppl 8): 14-6.
45. Bartalena L, Tanda ML, Piantanida E, Lai A. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003, 19: 155-63.
46. Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 2000, 129: 618-22.
47. Balazs C, Kiss E, Vamos A, Molnar I, Farid NR. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO): a pilot study. J Clin Endocrinol Metab 1997, 82: 1999-2002.
48. Finamor FE, Martins JRM, Nakanami D, Paiva ER, Manso PG, Furlanetto RP. Pentoxifylline (PTX)-An alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial. Eur J Ophthalmol 2004, 14: 277-83.
49. Bartalena L, Tanda ML, Medea A, Marcocci C, Pinchera A. Novel approaches to the management of Graves' ophthalmopathy. Hormones 2002, 1: 76-90.
50. Bartalena L, Wiersinga WM, Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004, 27: 295-301.
51. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2004, 1-4 (Epub ahead of print).
52. Starkey K, Heufelder A, Baker G, et al. Peroxisome proliferator-activated receptor-γ in thyroid eye disease: contraindication for thiazolidinedione use? J Clin Endocrinol Metab 2003, 88: 55-9.
53. Camp HS, Chaudry A, Leff T. A novel potent antagonist of peroxisome proliferator activated receptor γ blocks adipocyte differentiation but does not reverse the phenotype of terminally differentiated adipocytes. Endocrinology 2001, 142: 3207-13.
54. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002, 12: 855-60.
55. Bartalena L, Marcocci C, Pinchera A. Graves' ophthalmopathy: a preventable disease? Eur J Endocrinol 2002, 146: 457-61.
56. Hegedus L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest 2004, 27: 265-71.
57. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves' ophthalmopathy. Ann Intern Med 1998, 129: 632-5.
58. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996, 45: 477-81.
59. Moleti M, Mattina F, Salamone I, et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves' ophthalmopathy. Thyroid 2002, 13: 653-8.
60. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998, 338: 73-8.
61. Pinchera A, Bartalena L, Marcocci C. Radioiodine may be bad for Graves' ophthalmopathy, but... J Clin Endocrinol Metab 1995, 80: 342-5.
62. Marinó M, Morabito E, Altea MA, et al. Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves. J Endocrinol Invest 2005, 28: 280-4.